SYNAPS Dx is a privately held company focused on the research, development, and commercialization of the DISCERN™ diagnostic test for Alzheimer’s disease (AD). DISCERN™ is the first autopsy-validated skin test to accurately identify the presence of AD, informing a definitive diagnosis of AD in people recently diagnosed with dementia, even in cases of mixed dementia. DISCERN™ is commercially available under CLIA and is currently paid for by Medicare. Visit www.discerntest.com to learn more.